Products
Online Inquiry
Ruxolitinib
Cat. No.:
0225LY-0516
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and HPLC.
Size:
Add to basket
Product Overview
Description:
Ruxolitinib is a selective and potent inhibitor of JAK1/2 (IC50 = 3.3/2.8 nM) that triggers apoptosis and autophagy while demonstrating antitumor activity.
Synonym:
INCB018424; (R)-Ruxolitinib; 941678-49-5; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; R-Ruxolitinib; (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
CAS No.:
941678-49-5
Compound CID:
25126798
Formula:
C17H18N6
Formula Weight:
306.36
Specification
Targets&IC50:
JAK2: 2.8 nM (cell free); JAK1: 3.3 nM (cell free); TYK2: 19 nM (cell free)
Relative Density:
1.40 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Ruxolitinib can be used in hematology research, particularly in the study of JAK1 and JAK2 signaling in myeloproliferative neoplasms.
Library Information
Target:
JAK
Receptor:
JAK1; JAK2
Pathways:
Apoptosis; Chromatin/Epigenetic; Autophagy; JAK/STAT signaling; Stem cell regulation; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-7
Plate Location:
f9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
242 mg/mL; 789.92 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
<1 mg/mL
ALogP:
2.88
HBA_Count:
3
HBD_Count:
1
Rotatable Bond:
4
